Orthometrix, Inc. Announces First U.S. Sales of Its New Orbasone(TM) ESWT Pain Relief System to Treat Foot Pain

ORTHOMETRIX, INC. (OTCBB: OMRX) announced today that it
started selling in the United States its new Orbasone(TM) ESWT Pain
Relief System which received market approval from the U.S. Food and
Drug Administration ("FDA") for the treatment of chronic plantar
fasciitis (foot pain) on August 10, 2005.
   The Orbasone(TM) ESWT system uses high-energy shock waves to
relieve chronic plantar fasciitis. The technology is derived from a
proven non-invasive technology called Extracorporeal Shock Wave
Therapy, or ESWT, that has been used for the past 20 years to break up
kidney stones without the use of surgery (lithotripsy). Plantar
fasciitis is an inflammation of the plantar fascia, the thick strand
of collagen which is located under the foot and connects the calcaneus
(heel bone) to the metatarsals. This condition is extremely painful
and reduces mobility and quality of life. It affected approximately
38.6 million Americans in 2000 according to the American Podiatric
Medical Association (mainly athletes and the elderly).
   One of the first Orbasone(TM) ESWT units has been sold to
Manhattan Podiatry Associates, a prominent practice with several
offices in New York City, specializing in the medical, surgical, laser
treatment and ESWT of the foot. This practice was the East Coast site
for the Orbasone(TM) ESWT clinical study. Chief physicians Drs. J. E.
Mancuso and S. Abramow are board certified by the American Board of
Podiatric Surgery and Fellows of the American College of Foot and
Ankle Surgeons. They have been on the forefront of reconstruction and
laser surgery of the foot, acquiring an international reputation as
lecturers, authors of scientific publications and frequently quoted in
non-scientific media. They have been instrumental in successfully
completing the FDA clinical study to demonstrate the safety and
efficacy of the Orbasone(TM) ESWT system for the treatment of chronic
foot pain caused by plantar fasciitis. Orthometrix expects that, in
addition to purchasing the Orbasone(TM) ESWT system, Manhattan
Podiatry Associates will act as a reference site in the New York City
area to promote the Orbasone(TM) ESWT system to podiatrists and
orthopedic surgeons. Orthometrix would than have four sites that it
can use as reference and for demonstration in New York, Pennsylvania,
Illinois and California.
   Commenting on the Orbasone(TM) ESWT system, Reynald Bonmati,
Chairman and Chief Executive Officer of the Company, stated, "I am
very pleased with the interest the Orbasone(TM) ESWT system has
already generated among podiatrists and orthopedic surgeons since it
received market approval from the FDA last month. We have recruited a
direct sales force for the Orbasone(TM) ESWT system that is now
covering the entire country. With four locations that will be used not
only as reference sites but also to bring potential users to check the
outstanding performance of the Orbasone(TM) ESWT system, I have great
expectations for this device. We are currently assembling units in
Connecticut and building inventory to respond to the expected demand.
The Orbasone(TM) ESWT system is the only ESWT device approved in the
United States by the FDA for the treatment of chronic plantar
fasciitis that is also manufactured in the United States. Our intent
is to make ESWT treatment more affordable to a larger segment of the
U.S. population."

   Orthometrix, Inc. (the "Company") markets, sells and services
several musculoskeletal product lines used in pharmaceutical research,
diagnostics and monitoring of bone and muscle disorders, sports
medicine, rehabilitative medicine, physical therapy and pain
management.
   Our Web sites are www.orthometrix.net, www.vibraflex.com and
www.orbasone.com.

   "Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995: The statements which are not historical facts
contained in this release are forward-looking statements that involve
risk and uncertainties, including, but not limited to acceptance and
demand for new products, he impact of competitive products and
pricing, the regulatory environment, any effect on future financial
results from efforts to broaden the Company's position in the
rehabilitation, physical therapy and musculoskeletal markets, any
potential impact on sales of the Orbasone in North America, and other
risks and uncertainties detailed in the documents periodically filed
with the Securities and Exchange Commission, such as the Company's
most recent reports on Forms 10-KSB , 10-QSB ad 8-K. These risks and
uncertainties could cause actual results to differ materially from
those expected and/or contained in the forward-looking statements. Any
forward-looking statement made in this release is made as of the date
of this release and the Company assumes no obligation, subject to
applicable law, to update such forward-looking statement.